首页 > 最新文献

Apmis最新文献

英文 中文
Decreased T-cell response against latent cytomegalovirus infection does not correlate with anti-IFN autoantibodies in patients with APECED 在 APECED 患者中,针对潜伏巨细胞病毒感染的 T 细胞反应降低与抗 IFN 自身抗体无关。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-07 DOI: 10.1111/apm.13458
Iivo Hetemäki, Nelli Heikkilä, Pärt Peterson, Eliisa Kekäläinen, Nick Willcox, Wolff Anette S. B., Hanna Jarva, T Petteri Arstila

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an inborn error of immunity affecting both multiple endocrine organs and susceptibility to candidiasis, each with an autoimmune basis. Recently, high titer neutralizing anti-type I interferon (IFN) autoantibodies have been linked with increased severity of SARS-CoV-2 and varicella zoster virus infections in APECED patients. Examining immunity against cytomegalovirus (CMV), we found a higher prevalence of anti-CMV IgG antibodies in patients with APECED (N = 19) than in 44 healthy controls (90% vs 64%, p = 0.04); the similar difference in their IgG levels did not achieve significance (95 ± 74 vs 64 ± 35 IU/mL, ns.). In contrast, the frequency of CMV-specific T cells was lower (804 ± 718/million vs 1591 ± 972/million PBMC p = 0.03). We saw no correlations between levels of anti-CMV IgG and anti-IFN antibodies in APECED patients or in a separate cohort of patients with thymoma (n = 70), over 60% of whom also had anti-IFN antibodies. Our results suggest a dysregulated response to CMV in APECED patients and highlight immunodeficiency to viral infections as part of the disease spectrum.

自身免疫性多内分泌病-念珠菌病-外皮营养不良症(APECED)是一种先天性免疫错误,同时影响多个内分泌器官和对念珠菌病的易感性,每种疾病都有自身免疫基础。最近,高滴度中和抗 I 型干扰素(IFN)自身抗体与 APECED 患者感染 SARS-CoV-2 和水痘带状疱疹病毒的严重程度增加有关。在研究巨细胞病毒(CMV)免疫时,我们发现 APECED 患者(19 人)的抗 CMV IgG 抗体的流行率高于 44 名健康对照者(90% vs 64%,P = 0.04);他们的 IgG 水平的类似差异没有达到显著性(95 ± 74 vs 64 ± 35 IU/mL,ns.)。相比之下,CMV 特异性 T 细胞的频率较低(804 ± 718/百万对 1591 ± 972/百万 PBMC,P = 0.03)。我们发现,在 APECED 患者或另一个胸腺瘤患者队列(n = 70)中,抗 CMV IgG 和抗 IFN 抗体的水平之间没有相关性,其中超过 60% 的患者也有抗 IFN 抗体。我们的研究结果表明,APECED 患者对 CMV 的反应失调,并强调病毒感染免疫缺陷是该疾病谱的一部分。
{"title":"Decreased T-cell response against latent cytomegalovirus infection does not correlate with anti-IFN autoantibodies in patients with APECED","authors":"Iivo Hetemäki,&nbsp;Nelli Heikkilä,&nbsp;Pärt Peterson,&nbsp;Eliisa Kekäläinen,&nbsp;Nick Willcox,&nbsp;Wolff Anette S. B.,&nbsp;Hanna Jarva,&nbsp;T Petteri Arstila","doi":"10.1111/apm.13458","DOIUrl":"10.1111/apm.13458","url":null,"abstract":"<p>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an inborn error of immunity affecting both multiple endocrine organs and susceptibility to candidiasis, each with an autoimmune basis. Recently, high titer neutralizing anti-type I interferon (IFN) autoantibodies have been linked with increased severity of SARS-CoV-2 and <i>varicella zoster</i> virus infections in APECED patients. Examining immunity against cytomegalovirus (CMV), we found a higher prevalence of anti-CMV IgG antibodies in patients with APECED (N = 19) than in 44 healthy controls (90% vs 64%, p = 0.04); the similar difference in their IgG levels did not achieve significance (95 ± 74 vs 64 ± 35 IU/mL, ns.). In contrast, the frequency of CMV-specific T cells was lower (804 ± 718/million vs 1591 ± 972/million PBMC p = 0.03). We saw no correlations between levels of anti-CMV IgG and anti-IFN antibodies in APECED patients or in a separate cohort of patients with thymoma (n = 70), over 60% of whom also had anti-IFN antibodies. Our results suggest a dysregulated response to CMV in APECED patients and highlight immunodeficiency to viral infections as part of the disease spectrum.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 11","pages":"881-887"},"PeriodicalIF":2.2,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13458","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis 真实世界的数据证实,elexacftor/tezacaftor/ivacaftor调节剂可将符合条件的囊性纤维化患者的汗液氯化物浓度减半。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-02 DOI: 10.1111/apm.13453
Thomas Bryrup, Daniel Faurholt-Jepsen, Tacjana Pressler, Esben Herborg Henriksen, Christian Leo-Hansen, Bibi Uhre Nielsen, Christine Højte, Inger Hee Mabuza Mathiesen, Terese L. Katzenstein, Majbritt Jeppesen, Søren Jensen-Fangel, Hanne Vebert Olesen, Marianne Skov, Tavs Qvist, Mette Frahm Olsen, the TransformCF Study Group

Sweat chloride concentration, a diagnostic feature in cystic fibrosis (CF), reflects CF transmembrane conductance regulator (CFTR) activity. CFTR modulator therapies, especially elexacaftor/tezacaftor/ivacaftor (ETI), has improved CF outcomes. We report nationwide, real-world data on sweat chloride concentration in people with CF (pwCF) with and without modulator therapies. All Danish pwCF with a minimum of one F508del allele were included. Sweat chloride measurements were stratified by genotype and modulator treatment. Differences were assessed using mixed-effects models. We included 977 sweat chloride measurements from 430 pwCF, 71% of which were F508del homozygous. Heterozygous and homozygous ETI-treated pwCF had an estimated mean sweat chloride concentration of 43 mmol/L (95% confidence interval: 39; 48) and 43 mmol/L (39; 47), respectively—48% and 59% lower than those without treatment. High variation in concentrations remained regardless of treatment status. Despite ETI treatment, 27% heterozygous and 23% homozygous pwCF had elevated concentrations (≥60 mmol/L). These real-world data confirm a substantial decrease in sweat chloride concentration during modulator treatment, especially ETI, where mean concentrations halved. However, large variation remained, including persistently high concentrations. These findings emphasize the potential of sweat chloride concentration as a treatment response biomarker and the need to explore its heterogeneity and relationship with clinical outcomes.

汗液氯化物浓度是囊性纤维化(CF)的诊断特征之一,它反映了 CF 跨膜传导调节器(CFTR)的活性。CFTR 调节器疗法,尤其是 elexacaftor/tezacaftor/ivacaftor (ETI),改善了 CF 的治疗效果。我们报告了使用和未使用调节剂疗法的 CF 患者(pwCF)的汗液氯化物浓度的全国性真实数据。我们纳入了所有至少有一个 F508del 等位基因的丹麦 CF 患者。根据基因型和调节剂治疗方法对汗液氯化物进行分层测量。差异采用混合效应模型进行评估。我们纳入了来自 430 名 pwCF 的 977 次汗液氯化物测量结果,其中 71% 为 F508del 等位基因。经 ETI 治疗的杂合子和同源杂合子 pwCF 的估计平均汗液氯化物浓度分别为 43 mmol/L (95% 置信区间:39; 48) 和 43 mmol/L (39; 47),比未经治疗者分别低 48% 和 59%。无论治疗情况如何,浓度的差异仍然很大。尽管接受了 ETI 治疗,但仍有 27% 的杂合子和 23% 的同合子 pwCF 浓度升高(≥60 mmol/L)。这些真实世界的数据证实,在调节剂治疗期间,尤其是 ETI 治疗期间,汗液中的氯化物浓度大幅下降,平均浓度减半。然而,差异仍然很大,包括持续的高浓度。这些发现强调了汗液氯化物浓度作为治疗反应生物标志物的潜力,以及探索其异质性和与临床结果关系的必要性。
{"title":"Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis","authors":"Thomas Bryrup,&nbsp;Daniel Faurholt-Jepsen,&nbsp;Tacjana Pressler,&nbsp;Esben Herborg Henriksen,&nbsp;Christian Leo-Hansen,&nbsp;Bibi Uhre Nielsen,&nbsp;Christine Højte,&nbsp;Inger Hee Mabuza Mathiesen,&nbsp;Terese L. Katzenstein,&nbsp;Majbritt Jeppesen,&nbsp;Søren Jensen-Fangel,&nbsp;Hanne Vebert Olesen,&nbsp;Marianne Skov,&nbsp;Tavs Qvist,&nbsp;Mette Frahm Olsen,&nbsp;the TransformCF Study Group","doi":"10.1111/apm.13453","DOIUrl":"10.1111/apm.13453","url":null,"abstract":"<p>Sweat chloride concentration, a diagnostic feature in cystic fibrosis (CF), reflects CF transmembrane conductance regulator (CFTR) activity. CFTR modulator therapies, especially elexacaftor/tezacaftor/ivacaftor (ETI), has improved CF outcomes. We report nationwide, real-world data on sweat chloride concentration in people with CF (pwCF) with and without modulator therapies. All Danish pwCF with a minimum of one F508del allele were included. Sweat chloride measurements were stratified by genotype and modulator treatment. Differences were assessed using mixed-effects models. We included 977 sweat chloride measurements from 430 pwCF, 71% of which were F508del homozygous. Heterozygous and homozygous ETI-treated pwCF had an estimated mean sweat chloride concentration of 43 mmol/L (95% confidence interval: 39; 48) and 43 mmol/L (39; 47), respectively—48% and 59% lower than those without treatment. High variation in concentrations remained regardless of treatment status. Despite ETI treatment, 27% heterozygous and 23% homozygous pwCF had elevated concentrations (≥60 mmol/L). These real-world data confirm a substantial decrease in sweat chloride concentration during modulator treatment, especially ETI, where mean concentrations halved. However, large variation remained, including persistently high concentrations. These findings emphasize the potential of sweat chloride concentration as a treatment response biomarker and the need to explore its heterogeneity and relationship with clinical outcomes.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 10","pages":"728-733"},"PeriodicalIF":2.2,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13453","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A mathematical description of nonself for biallelic genetic systems in pregnancy, transfusion, and transplantation 妊娠、输血和移植中的双偶联遗传系统的非自我数学描述。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-19 DOI: 10.1111/apm.13457
Klaus Rieneck

A central issue in immunology is the immunological response against nonself. The prerequisite for a specific immunological response is the exposure to the immune system of a nonself antigen. Mathematical equations are presented, which define the fraction of all outcomes with a nonself allele in biallelic systems at the population level in pregnancy and transfusion/transplantation medicine. When designing assays, the mathematical descriptions can be used for estimating the number of genetic markers necessary to obtain a predetermined probability level in detecting nonself alleles of a given frequency. For instance, the equations can be helpful in the design of assays, where the nonself allele can be detected by analysis of cfDNA in plasma from pregnant women, to estimate fetal fraction or to monitor changes in cfDNA in plasma of transplantation patients. The equations give exact, quantitative descriptions of all nonself situations in pregnancy and transfusion/transplantation.

免疫学的一个核心问题是针对非自身的免疫反应。特异性免疫反应的前提是免疫系统接触到非自身抗原。本文提出了数学方程,定义了在妊娠和输血/移植医学中,双等位基因系统中所有结果中带有非自身等位基因的比例。在设计检测方法时,数学描述可用于估算在检测给定频率的非等位基因时,为获得预定概率水平所需的遗传标记物数量。例如,在设计检测方法时,可以通过分析孕妇血浆中的 cfDNA 来检测非自身等位基因,从而估算胎儿分数或监测移植患者血浆中 cfDNA 的变化。该方程对妊娠和输血/移植中的所有非等位基因情况都给出了精确的定量描述。
{"title":"A mathematical description of nonself for biallelic genetic systems in pregnancy, transfusion, and transplantation","authors":"Klaus Rieneck","doi":"10.1111/apm.13457","DOIUrl":"10.1111/apm.13457","url":null,"abstract":"<p>A central issue in immunology is the immunological response against nonself. The prerequisite for a specific immunological response is the exposure to the immune system of a nonself antigen. Mathematical equations are presented, which define the fraction of all outcomes with a nonself allele in biallelic systems at the population level in pregnancy and transfusion/transplantation medicine. When designing assays, the mathematical descriptions can be used for estimating the number of genetic markers necessary to obtain a predetermined probability level in detecting nonself alleles of a given frequency. For instance, the equations can be helpful in the design of assays, where the nonself allele can be detected by analysis of cfDNA in plasma from pregnant women, to estimate fetal fraction or to monitor changes in cfDNA in plasma of transplantation patients. The equations give exact, quantitative descriptions of all nonself situations in pregnancy and transfusion/transplantation.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 11","pages":"787-796"},"PeriodicalIF":2.2,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13457","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141730988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the role of mesenchymal stem cells in modulating immune responses via Treg and Th2 cell activation: insights from mouse model of multiple sclerosis 探索间充质干细胞在通过Treg和Th2细胞激活调节免疫反应中的作用:多发性硬化症小鼠模型的启示。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-19 DOI: 10.1111/apm.13456
Abdolvahid Sadeghnejad, Alireza Pazoki, Esmaeil Yazdanpanah, Seyed-Alireza Esmaeili, Bahman Yousefi, Bijan Sadighi-Moghaddam, Rasoul Baharlou, Dariush Haghmorad

Multiple sclerosis is a demyelinating neurodegenerative disease, and its animal model, experimental autoimmune encephalomyelitis (EAE), exhibits immunological and clinical similarities. The study aimed to examine mechanisms underlying therapeutic effects of mesenchymal stem cell administration in EAE. C57BL/6 mice were separated into control and treatment groups (T1, T2, and T3); EAE was induced in all animals. Clinical examinations were conducted daily, and on 25th day, animals were sacrificed, and spinal cord was stained for histological analysis. Additionally, spleen cell proliferation assay, assessments of cytokine, and gene expression in both spinal cord and spleen cells were performed. The results indicated a significant reduction in clinical symptoms among treatment groups compared to control group. Histological analyses revealed decreased infiltration of lymphocytes into the spinal cord and reduced demyelinated areas in treatment groups compared to control group. Cytokine production of IL-10, TGF-β, and IL-4 were significantly enhanced and IFN-γ and TNF-α in treatment groups were decreased relative to control group. Also, gene expression of CTLA-4, PD-1, IL-27, and IL-33 indicated a significant increase in treatment groups. The administration of MSCs significantly improved clinical symptoms, attenuated inflammation, and reduced spinal cord demyelination in EAE, suggesting a potential protective effect on disease progression.

多发性硬化症是一种脱髓鞘性神经退行性疾病,其动物模型实验性自身免疫性脑脊髓炎(EAE)在免疫学和临床上表现出相似性。该研究旨在探讨间充质干细胞对EAE的治疗作用机制。C57BL/6小鼠被分为对照组和治疗组(T1、T2和T3),所有动物均诱发EAE。每天对动物进行临床检查,第25天将动物处死,并对脊髓染色进行组织学分析。此外,还进行了脾脏细胞增殖试验、细胞因子评估以及脊髓和脾脏细胞的基因表达。结果表明,与对照组相比,治疗组的临床症状明显减轻。组织学分析显示,与对照组相比,治疗组淋巴细胞向脊髓的浸润减少,脱髓鞘区域缩小。与对照组相比,治疗组细胞因子 IL-10、TGF-β 和 IL-4 的分泌明显增加,IFN-γ 和 TNF-α 的分泌减少。此外,治疗组中 CTLA-4、PD-1、IL-27 和 IL-33 的基因表达也有明显增加。服用间充质干细胞能明显改善EAE患者的临床症状、减轻炎症反应并减少脊髓脱髓鞘,这表明间充质干细胞对疾病的进展具有潜在的保护作用。
{"title":"Exploring the role of mesenchymal stem cells in modulating immune responses via Treg and Th2 cell activation: insights from mouse model of multiple sclerosis","authors":"Abdolvahid Sadeghnejad,&nbsp;Alireza Pazoki,&nbsp;Esmaeil Yazdanpanah,&nbsp;Seyed-Alireza Esmaeili,&nbsp;Bahman Yousefi,&nbsp;Bijan Sadighi-Moghaddam,&nbsp;Rasoul Baharlou,&nbsp;Dariush Haghmorad","doi":"10.1111/apm.13456","DOIUrl":"10.1111/apm.13456","url":null,"abstract":"<p>Multiple sclerosis is a demyelinating neurodegenerative disease, and its animal model, experimental autoimmune encephalomyelitis (EAE), exhibits immunological and clinical similarities. The study aimed to examine mechanisms underlying therapeutic effects of mesenchymal stem cell administration in EAE. C57BL/6 mice were separated into control and treatment groups (T1, T2, and T3); EAE was induced in all animals. Clinical examinations were conducted daily, and on 25th day, animals were sacrificed, and spinal cord was stained for histological analysis. Additionally, spleen cell proliferation assay, assessments of cytokine, and gene expression in both spinal cord and spleen cells were performed. The results indicated a significant reduction in clinical symptoms among treatment groups compared to control group. Histological analyses revealed decreased infiltration of lymphocytes into the spinal cord and reduced demyelinated areas in treatment groups compared to control group. Cytokine production of IL-10, TGF-β, and IL-4 were significantly enhanced and IFN-γ and TNF-α in treatment groups were decreased relative to control group. Also, gene expression of CTLA-4, PD-1, IL-27, and IL-33 indicated a significant increase in treatment groups. The administration of MSCs significantly improved clinical symptoms, attenuated inflammation, and reduced spinal cord demyelination in EAE, suggesting a potential protective effect on disease progression.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 11","pages":"888-899"},"PeriodicalIF":2.2,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141730989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unravelling the intricacies of Porphyromonas gingivalis: virulence factors, lifecycle dynamics and phytochemical interventions for periodontal disease management 揭开牙龈卟啉单胞菌的神秘面纱:毒力因子、生命周期动态和牙周病管理的植物化学干预措施。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-19 DOI: 10.1111/apm.13440
Rubeen Nadaf, Vijay M. Kumbar, Shridhar Ghagane

Porphyromonas gingivalis is a gram-negative anaerobic bacterium recognized for its pivotal role in the pathogenesis of periodontal diseases. This review covers an overview of the virulence factors and lifecycle stages of P. gingivalis, with a specific focus on attachment and colonization, biofilm formation, growth and multiplication, dormancy survival and dissemination. Additionally, we explore the significance of inter-bacterial cross-feeding within biofilms. Furthermore, we discuss potential phytochemical-based strategies to target P. gingivalis, including the use of curcumin, apigenin, quercetin and resveratrol. Understanding the virulence factors and lifecycle stages of P. gingivalis, along with the promising phytochemical-based interventions, holds promise for advancing strategies in periodontal disease management and oral health promotion.

牙龈卟啉单胞菌(Porphyromonas gingivalis)是一种革兰氏阴性厌氧菌,在牙周疾病的发病机制中起着举足轻重的作用。本综述概述了牙龈卟啉单胞菌的毒力因子和生命周期阶段,重点关注附着和定植、生物膜形成、生长和繁殖、休眠存活和传播。此外,我们还探讨了生物膜内细菌间交叉觅食的意义。此外,我们还讨论了针对牙龈脓疱病的潜在植物化学策略,包括姜黄素、芹菜素、槲皮素和白藜芦醇的使用。了解牙龈脓疱疮杆菌的毒力因子和生命周期阶段以及有前景的植物化学干预措施,有望推进牙周疾病管理和口腔健康促进策略。
{"title":"Unravelling the intricacies of Porphyromonas gingivalis: virulence factors, lifecycle dynamics and phytochemical interventions for periodontal disease management","authors":"Rubeen Nadaf,&nbsp;Vijay M. Kumbar,&nbsp;Shridhar Ghagane","doi":"10.1111/apm.13440","DOIUrl":"10.1111/apm.13440","url":null,"abstract":"<p><i>Porphyromonas gingivalis</i> is a gram-negative anaerobic bacterium recognized for its pivotal role in the pathogenesis of periodontal diseases. This review covers an overview of the virulence factors and lifecycle stages of <i>P. gingivalis</i>, with a specific focus on attachment and colonization, biofilm formation, growth and multiplication, dormancy survival and dissemination. Additionally, we explore the significance of inter-bacterial cross-feeding within biofilms. Furthermore, we discuss potential phytochemical-based strategies to target <i>P. gingivalis</i>, including the use of curcumin, apigenin, quercetin and resveratrol. Understanding the virulence factors and lifecycle stages of <i>P. gingivalis</i>, along with the promising phytochemical-based interventions, holds promise for advancing strategies in periodontal disease management and oral health promotion.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 9","pages":"611-624"},"PeriodicalIF":2.2,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141730990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemical expression of SATB2 and PAX8 in differentiating primary from metastatic ovarian mucinous neoplasms SATB2 和 PAX8 在区分原发性和转移性卵巢黏液瘤中的免疫组化表达。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-15 DOI: 10.1111/apm.13449
Rana Ahmed El Ghondakly, Salwa Ibrahim El Haddad, Magda Mohamed AbdelSalam, Ola Hassan Nada, Rola Mohamed Farid, Laila M. Farid

Accurate stratification of an ovarian mucinous neoplasm as primary or secondary is always challenging as they show overlapping histomorphological and immunohistochemical features. Immunohistochemical staining for SATB2 and PAX8 was performed on 80 cases of mucinous ovarian neoplasms subdivided into 53 primary [25 primary ovarian mucinous carcinomas (POMCs) and 28 mucinous borderline tumors (MBTs)] and 27 secondary (12 of colonic origin, 7 of appendiceal origin, and 8 of gastric origin). Expression was correlated with different clinicopathologic parameters. PAX8-positive immunostaining was detected in 38 out of 53 cases (71.69%) of primary ovarian mucinous neoplasms (POMNs) with null positivity in the secondary ovarian mucinous tumors (0/27). SATB2-positive expression was detected in 16 out of 27 cases (59.26%) of the secondary ovarian mucinous tumors. None of the studied POMNs showed any positive immunostaining for SATB2 (0/53). A profile of SATB2/PAX8+ and SATB2+/PAX8 can be used to differentiate POMNCs from secondary ovarian mucinous tumors of GI origin, respectively, with 100% specificity. PAX8 expression is associated with some clinicopathologic parameters providing the basis for the possible usage of PAX8 as prognostic marker.

由于卵巢黏液瘤的组织形态学和免疫组化特征相互重叠,因此准确划分卵巢黏液瘤是原发性还是继发性一直是个难题。我们对 80 例卵巢粘液性肿瘤进行了 SATB2 和 PAX8 的免疫组化染色,这些肿瘤被细分为 53 例原发性肿瘤(25 例原发性卵巢粘液癌(POMC)和 28 例粘液性边界瘤(MBT))和 27 例继发性肿瘤(12 例结肠源性肿瘤、7 例阑尾源性肿瘤和 8 例胃源性肿瘤)。PAX8的表达与不同的临床病理参数相关。在 53 例原发性卵巢粘液性肿瘤(POMNs)中,有 38 例(71.69%)检测到 PAX8 阳性免疫染色,而在继发性卵巢粘液性肿瘤(0/27)中则为零阳性。在 27 例继发性卵巢黏液瘤中,有 16 例(59.26%)检测到 SATB2 阳性表达。在所研究的 POMNs 中,没有一个出现 SATB2 阳性免疫染色(0/53)。SATB2-/PAX8+和SATB2+/PAX8-可分别用于区分POMNCs和消化道来源的继发性卵巢粘液性肿瘤,特异性为100%。PAX8 的表达与一些临床病理参数相关,这为将 PAX8 用作预后标志物提供了依据。
{"title":"Immunohistochemical expression of SATB2 and PAX8 in differentiating primary from metastatic ovarian mucinous neoplasms","authors":"Rana Ahmed El Ghondakly,&nbsp;Salwa Ibrahim El Haddad,&nbsp;Magda Mohamed AbdelSalam,&nbsp;Ola Hassan Nada,&nbsp;Rola Mohamed Farid,&nbsp;Laila M. Farid","doi":"10.1111/apm.13449","DOIUrl":"10.1111/apm.13449","url":null,"abstract":"<p>Accurate stratification of an ovarian mucinous neoplasm as primary or secondary is always challenging as they show overlapping histomorphological and immunohistochemical features. Immunohistochemical staining for SATB2 and PAX8 was performed on 80 cases of mucinous ovarian neoplasms subdivided into 53 primary [25 primary ovarian mucinous carcinomas (POMCs) and 28 mucinous borderline tumors (MBTs)] and 27 secondary (12 of colonic origin, 7 of appendiceal origin, and 8 of gastric origin). Expression was correlated with different clinicopathologic parameters. PAX8-positive immunostaining was detected in 38 out of 53 cases (71.69%) of primary ovarian mucinous neoplasms (POMNs) with null positivity in the secondary ovarian mucinous tumors (0/27). SATB2-positive expression was detected in 16 out of 27 cases (59.26%) of the secondary ovarian mucinous tumors. None of the studied POMNs showed any positive immunostaining for SATB2 (0/53). A profile of SATB2<sup>−</sup>/PAX8<sup>+</sup> and SATB2<sup>+</sup>/PAX8<sup>−</sup> can be used to differentiate POMNCs from secondary ovarian mucinous tumors of GI origin, respectively, with 100% specificity. PAX8 expression is associated with some clinicopathologic parameters providing the basis for the possible usage of PAX8 as prognostic marker.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 10","pages":"706-717"},"PeriodicalIF":2.2,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacteriophage therapy and infective endocarditis – is it realistic? 噬菌体疗法和感染性心内膜炎--现实吗?
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-15 DOI: 10.1111/apm.13455
Emilie C. Pedersen, Christian Johann Lerche, Franziska Angelica Schwartz, Oana Ciofu, Joana Azeredo, Kim Thomsen, Claus Moser

Infective endocarditis (IE) is a severe infection of the inner heart. Even with current standard treatment, the mean in-hospital mortality is as high as 15–20%, and 1-year mortality is up to 40% for left-sided IE. Importantly, IE mortality rates have not changed substantially over the past 30 years, and the incidence of IE is rising. The treatment is challenging due to the bacterial biofilm mode of growth inside the heart valve vegetations, resulting in antibiotic tolerance. Achieving sufficient antibiotic anti-biofilm concentrations in the biofilms of the heart valve vegetations is problematic, even with high-dose and long-term antibiotic therapy. The increasing prevalence of IE caused by antibiotic-resistant bacteria adds to the challenge. Therefore, adjunctive antibiotic-potentiating drug candidates and strategies are increasingly being investigated. Bacteriophage therapy is a reemerging antibacterial treatment strategy for difficult-to-treat infections, mainly biofilm-associated and caused by multidrug-resistant bacteria. However, significant knowledge gaps regarding the safety and efficacy of phage therapy impede more widespread implementation in clinical practice. Hopefully, future preclinical and clinical testing will reveal whether it is a viable treatment. The objective of the present review is to assess whether bacteriophage therapy is a realistic treatment for IE.

感染性心内膜炎(IE)是一种严重的内脏感染。即使采用目前的标准治疗,平均院内死亡率仍高达 15-20%,左侧 IE 的 1 年死亡率高达 40%。重要的是,在过去的 30 年中,IE 的死亡率没有发生实质性变化,而 IE 的发病率却在不断上升。由于细菌在心脏瓣膜植被内的生物膜生长模式导致抗生素耐受性,因此治疗具有挑战性。即使使用大剂量和长期的抗生素治疗,要在心脏瓣膜植被的生物膜中达到足够的抗生素抗生物膜浓度也很困难。由抗生素耐药菌引起的 IE 发病率不断上升,更加剧了这一挑战。因此,人们越来越多地研究辅助性抗生素增效候选药物和策略。噬菌体疗法是一种新兴的抗菌治疗策略,可用于治疗难以治疗的感染,主要是由多重耐药菌引起的生物膜相关感染。然而,噬菌体疗法的安全性和有效性方面还存在很大的知识差距,这阻碍了噬菌体疗法在临床实践中的广泛应用。希望未来的临床前和临床试验能揭示噬菌体疗法是否可行。本综述旨在评估噬菌体疗法是否是治疗 IE 的现实疗法。
{"title":"Bacteriophage therapy and infective endocarditis – is it realistic?","authors":"Emilie C. Pedersen,&nbsp;Christian Johann Lerche,&nbsp;Franziska Angelica Schwartz,&nbsp;Oana Ciofu,&nbsp;Joana Azeredo,&nbsp;Kim Thomsen,&nbsp;Claus Moser","doi":"10.1111/apm.13455","DOIUrl":"10.1111/apm.13455","url":null,"abstract":"<p>Infective endocarditis (IE) is a severe infection of the inner heart. Even with current standard treatment, the mean in-hospital mortality is as high as 15–20%, and 1-year mortality is up to 40% for left-sided IE. Importantly, IE mortality rates have not changed substantially over the past 30 years, and the incidence of IE is rising. The treatment is challenging due to the bacterial biofilm mode of growth inside the heart valve vegetations, resulting in antibiotic tolerance. Achieving sufficient antibiotic anti-biofilm concentrations in the biofilms of the heart valve vegetations is problematic, even with high-dose and long-term antibiotic therapy. The increasing prevalence of IE caused by antibiotic-resistant bacteria adds to the challenge. Therefore, adjunctive antibiotic-potentiating drug candidates and strategies are increasingly being investigated. Bacteriophage therapy is a reemerging antibacterial treatment strategy for difficult-to-treat infections, mainly biofilm-associated and caused by multidrug-resistant bacteria. However, significant knowledge gaps regarding the safety and efficacy of phage therapy impede more widespread implementation in clinical practice. Hopefully, future preclinical and clinical testing will reveal whether it is a viable treatment. The objective of the present review is to assess whether bacteriophage therapy is a realistic treatment for IE.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 10","pages":"675-687"},"PeriodicalIF":2.2,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the cross-protection of the Vero cell-derived attenuated influenza vaccines with compound adjuvant, through intranasal immunization 评估通过鼻内免疫接种含有复合佐剂的 Vero 细胞衍生减毒流感疫苗的交叉保护作用。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-03 DOI: 10.1111/apm.13448
Liu Ze, Song Shaohui, Huang Jinhai, Gao Hui

This study was to evaluate the sufficient safety and effect of the novel influenza vaccine program. It prepared new reassortant influenza virus, with high yield on Vero cells. According to the plaque counting, one dose LAIV was composed with 105 PFU of H1, H3, BY, and BV, respectively. Then mixed this LAIV with compound adjuvant, containing 500 μg/mL of carbopol971P and 50 μg/mL of tetanus toxin. That vaccination was called catt-flu. And it employed the GYZZ02 vaccine (commercialized freeze-dried LAIV, listed in China) as cohort analysis control. All mice received two doses of the vaccine, administered on days 0 and 14, respectively. That catt-flu program could induce more cross-protection with neutralizing antibody against heterogeneous types of influenza virus, not only based on HA but also NA protective antigen, through convenient nasal immunization, which had non-inferiority titter compared with the chicken embryo-derived GYZZ02 vaccine on safe and effect. The Vero cell-derived vaccine (LAIV) combined compound catt adjuvant (contain carbopol971P and tetanus toxin) could provide another safety and protective program of influenza vaccine by intranasal administration, as catt-flu program.

这项研究旨在评估新型流感疫苗计划的充分安全性和效果。该研究制备了新型流感病毒,其在 Vero 细胞上的产量很高。根据斑块计数,一剂 LAIV 分别由 105 PFU 的 H1、H3、BY 和 BV 组成。然后将 LAIV 与复合佐剂混合,复合佐剂含有 500 μg/mL 的 carbopol971P 和 50 μg/mL 的破伤风毒素。这种疫苗被称为 catt-flu。它采用GYZZ02疫苗(中国上市的商品化冻干LAIV)作为队列分析对照。所有小鼠分别在第0天和第14天接种了两剂疫苗。该流感疫苗方案通过便捷的鼻腔免疫,不仅能基于HA,还能基于NA保护性抗原诱导更多针对异型流感病毒的交叉保护性中和抗体,与鸡胚衍生的GYZZ02疫苗相比,在安全性和有效性方面滴度均无劣势。Vero细胞衍生疫苗(LAIV)联合复合卡他佐剂(含carbopol971P和破伤风毒素)可提供另一种安全、保护性的流感疫苗鼻内给药方案,即卡他流感方案。
{"title":"Evaluation of the cross-protection of the Vero cell-derived attenuated influenza vaccines with compound adjuvant, through intranasal immunization","authors":"Liu Ze,&nbsp;Song Shaohui,&nbsp;Huang Jinhai,&nbsp;Gao Hui","doi":"10.1111/apm.13448","DOIUrl":"10.1111/apm.13448","url":null,"abstract":"<p>This study was to evaluate the sufficient safety and effect of the novel influenza vaccine program. It prepared new reassortant influenza virus, with high yield on Vero cells. According to the plaque counting, one dose LAIV was composed with 10<sup>5</sup> PFU of H1, H3, BY, and BV, respectively. Then mixed this LAIV with compound adjuvant, containing 500 μg/mL of carbopol971P and 50 μg/mL of tetanus toxin. That vaccination was called <i>catt</i>-<i>flu</i>. And it employed the GYZZ02 vaccine (commercialized freeze-dried LAIV, listed in China) as cohort analysis control. All mice received two doses of the vaccine, administered on days 0 and 14, respectively. That <i>catt</i>-<i>flu</i> program could induce more cross-protection with neutralizing antibody against heterogeneous types of influenza virus, not only based on HA but also NA protective antigen, through convenient nasal immunization, which had non-inferiority titter compared with the chicken embryo-derived GYZZ02 vaccine on safe and effect. The Vero cell-derived vaccine (LAIV) combined compound catt adjuvant (contain carbopol971P and tetanus toxin) could provide another safety and protective program of influenza vaccine by intranasal administration, as <i>catt</i>-<i>flu</i> program.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 10","pages":"741-753"},"PeriodicalIF":2.2,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141496969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergence and fixation of SARS-CoV-2 minority variants in a chronically infected patient receiving therapy in Denmark 丹麦一名接受治疗的慢性感染患者体内出现并固定了 SARS-CoV-2 少数变种。
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-03 DOI: 10.1111/apm.13454
Jannik Fonager, Nikolaj Julian Skrøder Nytofte, Christian Højte Schouw, Christian B. Poulsen, Lothar Wiese, Anders Fomsgaard, Marc Bennedbæk, Morten Rasmussen, Xiaohui Chen Nielsen

SARS-CoV-2 variants of concern (VOC), such as Delta and Omicron have harbored mutations, which increased viral infectivity or ability to evade neutralizing antibodies. Immunocompromised patients might be a source of some of these emerging variants. In this study, we sequenced 17 consecutive samples from an immunocompromised patient with a long-term SARS-CoV-2 infection with the pre-VOC era lineage B.1.177.35. We here describe the emergence of 73 nonsynonymous minority variants in this patient and show that 10 of these mutations became dominant in the viral population during the treatment period. Four of these were seen throughout the infection period and had a very low global prevalence, although three of them were also observed later in the Alpha, Delta, and Omicron lineages. We also found that two adjacent nsp12 variants (M785I and S786P) belonged to different quasi-species and competed during the early stages of infection and remdesivir administration. This emphasizes the importance of ongoing genome surveillance of SARS-CoV-2 among immunocpromised patients.

令人担忧的 SARS-CoV-2 变种(VOC),如 Delta 和 Omicron 已发生变异,从而提高了病毒的感染力或逃避中和抗体的能力。免疫力低下的患者可能是其中一些新变种的来源。在本研究中,我们对一名长期感染 SARS-CoV-2 的免疫功能低下患者的 17 份连续样本进行了测序,该患者感染的是前 VOC 时代的 B.1.177.35 系。我们在此描述了该患者出现的 73 个非同义少数变异,并显示其中 10 个变异在治疗期间成为病毒群体中的优势变异。其中 4 个变异在整个感染期间都有出现,而且全球流行率很低,不过其中 3 个变异后来在 Alpha、Delta 和 Omicron 系中也有出现。我们还发现,两个相邻的 nsp12 变体(M785I 和 S786P)属于不同的准物种,并在感染和服用雷米替韦的早期阶段发生竞争。这强调了在免疫力低下的患者中持续进行 SARS-CoV-2 基因组监测的重要性。
{"title":"Emergence and fixation of SARS-CoV-2 minority variants in a chronically infected patient receiving therapy in Denmark","authors":"Jannik Fonager,&nbsp;Nikolaj Julian Skrøder Nytofte,&nbsp;Christian Højte Schouw,&nbsp;Christian B. Poulsen,&nbsp;Lothar Wiese,&nbsp;Anders Fomsgaard,&nbsp;Marc Bennedbæk,&nbsp;Morten Rasmussen,&nbsp;Xiaohui Chen Nielsen","doi":"10.1111/apm.13454","DOIUrl":"10.1111/apm.13454","url":null,"abstract":"<p>SARS-CoV-2 variants of concern (VOC), such as Delta and Omicron have harbored mutations, which increased viral infectivity or ability to evade neutralizing antibodies. Immunocompromised patients might be a source of some of these emerging variants. In this study, we sequenced 17 consecutive samples from an immunocompromised patient with a long-term SARS-CoV-2 infection with the pre-VOC era lineage B.1.177.35. We here describe the emergence of 73 nonsynonymous minority variants in this patient and show that 10 of these mutations became dominant in the viral population during the treatment period. Four of these were seen throughout the infection period and had a very low global prevalence, although three of them were also observed later in the Alpha, Delta, and Omicron lineages. We also found that two adjacent nsp12 variants (M785I and S786P) belonged to different quasi-species and competed during the early stages of infection and remdesivir administration. This emphasizes the importance of ongoing genome surveillance of SARS-CoV-2 among immunocpromised patients.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 10","pages":"734-740"},"PeriodicalIF":2.2,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13454","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141496968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peer-to-peer validation of Ki-67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought? 将病理质量圈中的 Ki-67 评分作为评估观察者间变异性的工具进行点对点验证:我们比想象的更好吗?
IF 2.2 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-07-01 DOI: 10.1111/apm.13451
Marit Bernhardt, Leonie Weinhold, Christine Sanders, Oliver Hommerding, Jan-Frederic Lau, Marieta Toma, Verena Tischler, Matthias Schmid, Tomasz Zienkiewicz, Ralf Hildenbrand, Peter Gerlach, Hui Zhou, Martin Braun, Gunnar Müller, Erich Sieber, Christian Marko, Glen Kristiansen

Ki-67, a nuclear protein expressed in all stages of cellular proliferation, is a valuable tool to assess tumor proliferation and has been linked to more aggressive tumor behavior. However, interlaboratory staining heterogeneity and inter-observer variability challenge its reproducibility. Round Robin tests are a suitable tool to standardize and harmonize immunohistochemical and molecular analyses in histopathology. The study investigates the interrater and interlaboratory reproducibility of Ki-67-scoring using both manual and automated approaches. Unstained TMA slides comprising diverse tumor types (breast cancer, neuroendocrine tumors, lymphomas, and head and neck squamous cell carcinoma) were distributed to six pathology laboratories, each employing their routine staining protocols. Manual and automated scoring methods were applied, and interrater and interlaboratory agreement assessed using intraclass correlation coefficients (ICC). The results highlight good-to-excellent reliability overall, with automated scoring demonstrating higher consistency (ICC 0.955) than manual scoring (ICC 0.871). Results were more variable when looking at the individual entities. Reliability remained good for lymphomas (ICC 0.878) and breast cancer (ICC 0.784) and was poor in well-differentiated neuroendocrine tumors (ICC 0.354). This study clearly advocates standardized practices and training to ensure consistency in Ki-67-assessment, and it demonstrates that this can be achieved in a peer-to-peer approach in local quality-circles.

Ki-67是一种在细胞增殖各阶段均有表达的核蛋白,是评估肿瘤增殖的重要工具,并与更具侵袭性的肿瘤行为有关。然而,实验室间染色异质性和观察者间的差异性对其可重复性提出了挑战。圆环测试是一种合适的工具,可用于标准化和协调组织病理学中的免疫组化和分子分析。本研究采用手动和自动方法,对 Ki-67 评分的重复性和实验室间的重复性进行了研究。由不同肿瘤类型(乳腺癌、神经内分泌肿瘤、淋巴瘤和头颈部鳞状细胞癌)组成的未染色 TMA 切片被分发到六家病理实验室,每家实验室都采用了各自的常规染色方案。采用手动和自动评分方法,并使用类内相关系数(ICC)评估了评分者之间和实验室之间的一致性。结果表明,总体可靠性从良好到优秀,自动评分的一致性(ICC 0.955)高于人工评分(ICC 0.871)。在观察单个实体时,结果的差异较大。淋巴瘤(ICC 0.878)和乳腺癌(ICC 0.784)的可靠性仍然较好,而分化良好的神经内分泌肿瘤(ICC 0.354)的可靠性较差。这项研究明确提倡标准化的操作和培训,以确保 Ki-67 评估的一致性,并证明这可以通过当地质量小组的同行间交流来实现。
{"title":"Peer-to-peer validation of Ki-67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?","authors":"Marit Bernhardt,&nbsp;Leonie Weinhold,&nbsp;Christine Sanders,&nbsp;Oliver Hommerding,&nbsp;Jan-Frederic Lau,&nbsp;Marieta Toma,&nbsp;Verena Tischler,&nbsp;Matthias Schmid,&nbsp;Tomasz Zienkiewicz,&nbsp;Ralf Hildenbrand,&nbsp;Peter Gerlach,&nbsp;Hui Zhou,&nbsp;Martin Braun,&nbsp;Gunnar Müller,&nbsp;Erich Sieber,&nbsp;Christian Marko,&nbsp;Glen Kristiansen","doi":"10.1111/apm.13451","DOIUrl":"10.1111/apm.13451","url":null,"abstract":"<p>Ki-67, a nuclear protein expressed in all stages of cellular proliferation, is a valuable tool to assess tumor proliferation and has been linked to more aggressive tumor behavior. However, interlaboratory staining heterogeneity and inter-observer variability challenge its reproducibility. Round Robin tests are a suitable tool to standardize and harmonize immunohistochemical and molecular analyses in histopathology. The study investigates the interrater and interlaboratory reproducibility of Ki-67-scoring using both manual and automated approaches. Unstained TMA slides comprising diverse tumor types (breast cancer, neuroendocrine tumors, lymphomas, and head and neck squamous cell carcinoma) were distributed to six pathology laboratories, each employing their routine staining protocols. Manual and automated scoring methods were applied, and interrater and interlaboratory agreement assessed using intraclass correlation coefficients (ICC). The results highlight good-to-excellent reliability overall, with automated scoring demonstrating higher consistency (ICC 0.955) than manual scoring (ICC 0.871). Results were more variable when looking at the individual entities. Reliability remained good for lymphomas (ICC 0.878) and breast cancer (ICC 0.784) and was poor in well-differentiated neuroendocrine tumors (ICC 0.354). This study clearly advocates standardized practices and training to ensure consistency in Ki-67-assessment, and it demonstrates that this can be achieved in a peer-to-peer approach in local quality-circles.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 10","pages":"718-727"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13451","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141475771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Apmis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1